Home/Filings/4/0000950103-19-003374
4//SEC Filing

Venrock Associates VII, L.P. 4

Accession 0000950103-19-003374

CIK 0001642545other

Filed

Mar 12, 8:00 PM ET

Accepted

Mar 13, 4:31 PM ET

Size

24.9 KB

Accession

0000950103-19-003374

Insider Transaction Report

Form 4
Period: 2019-03-11
Transactions
  • Conversion

    Series C Convertible Preferred Stock

    2019-03-11+1,016,4920 total(indirect: By Funds)
    Common Stock (1,016,492 underlying)
  • Conversion

    Common Stock

    2019-03-11+1,105,5291,105,529 total(indirect: By Funds)
  • Conversion

    Series B Convertible Preferred Stock

    2019-03-11+1,105,5290 total(indirect: By Funds)
    Common Stock (1,105,529 underlying)
  • Conversion

    Common Stock

    2019-03-11+1,016,4922,122,021 total(indirect: By Funds)
Transactions
  • Conversion

    Series C Convertible Preferred Stock

    2019-03-11+1,016,4920 total(indirect: By Funds)
    Common Stock (1,016,492 underlying)
  • Conversion

    Series B Convertible Preferred Stock

    2019-03-11+1,105,5290 total(indirect: By Funds)
    Common Stock (1,105,529 underlying)
  • Conversion

    Common Stock

    2019-03-11+1,105,5291,105,529 total(indirect: By Funds)
  • Conversion

    Common Stock

    2019-03-11+1,016,4922,122,021 total(indirect: By Funds)
Transactions
  • Conversion

    Common Stock

    2019-03-11+1,105,5291,105,529 total(indirect: By Funds)
  • Conversion

    Series B Convertible Preferred Stock

    2019-03-11+1,105,5290 total(indirect: By Funds)
    Common Stock (1,105,529 underlying)
  • Conversion

    Series C Convertible Preferred Stock

    2019-03-11+1,016,4920 total(indirect: By Funds)
    Common Stock (1,016,492 underlying)
  • Conversion

    Common Stock

    2019-03-11+1,016,4922,122,021 total(indirect: By Funds)
Transactions
  • Conversion

    Common Stock

    2019-03-11+1,105,5291,105,529 total(indirect: By Funds)
  • Conversion

    Common Stock

    2019-03-11+1,016,4922,122,021 total(indirect: By Funds)
  • Conversion

    Series B Convertible Preferred Stock

    2019-03-11+1,105,5290 total(indirect: By Funds)
    Common Stock (1,105,529 underlying)
  • Conversion

    Series C Convertible Preferred Stock

    2019-03-11+1,016,4920 total(indirect: By Funds)
    Common Stock (1,016,492 underlying)
Transactions
  • Conversion

    Common Stock

    2019-03-11+1,105,5291,105,529 total(indirect: By Funds)
  • Conversion

    Common Stock

    2019-03-11+1,016,4922,122,021 total(indirect: By Funds)
  • Conversion

    Series B Convertible Preferred Stock

    2019-03-11+1,105,5290 total(indirect: By Funds)
    Common Stock (1,105,529 underlying)
  • Conversion

    Series C Convertible Preferred Stock

    2019-03-11+1,016,4920 total(indirect: By Funds)
    Common Stock (1,016,492 underlying)
Shah Nimish P
10% Owner
Transactions
  • Conversion

    Series B Convertible Preferred Stock

    2019-03-11+1,105,5290 total(indirect: By Funds)
    Common Stock (1,105,529 underlying)
  • Conversion

    Common Stock

    2019-03-11+1,016,4922,122,021 total(indirect: By Funds)
  • Conversion

    Common Stock

    2019-03-11+1,105,5291,105,529 total(indirect: By Funds)
  • Conversion

    Series C Convertible Preferred Stock

    2019-03-11+1,016,4920 total(indirect: By Funds)
    Common Stock (1,016,492 underlying)
Koh Bong Y
10% Owner
Transactions
  • Conversion

    Series C Convertible Preferred Stock

    2019-03-11+1,016,4920 total(indirect: By Funds)
    Common Stock (1,016,492 underlying)
  • Conversion

    Common Stock

    2019-03-11+1,105,5291,105,529 total(indirect: By Funds)
  • Conversion

    Common Stock

    2019-03-11+1,016,4922,122,021 total(indirect: By Funds)
  • Conversion

    Series B Convertible Preferred Stock

    2019-03-11+1,105,5290 total(indirect: By Funds)
    Common Stock (1,105,529 underlying)
Transactions
  • Conversion

    Common Stock

    2019-03-11+1,105,5291,105,529 total(indirect: By Funds)
  • Conversion

    Series C Convertible Preferred Stock

    2019-03-11+1,016,4920 total(indirect: By Funds)
    Common Stock (1,016,492 underlying)
  • Conversion

    Common Stock

    2019-03-11+1,016,4922,122,021 total(indirect: By Funds)
  • Conversion

    Series B Convertible Preferred Stock

    2019-03-11+1,105,5290 total(indirect: By Funds)
    Common Stock (1,105,529 underlying)
Footnotes (4)
  • [F1]Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.
  • [F2]Consists of 745,139 shares of convertible preferred stock held by Venrock Associates VII, L.P., 212,500 shares of convertible preferred stock held by Venrock Healthcare Capital Partners II, L.P., 61,725 shares of convertible preferred stock held by Venrock Partners VII, L.P. and 86,165 shares of convertible preferred stock held by VHCP Co-Investment Holdings II, LLC.
  • [F3]Consists of 382,238 shares of convertible preferred stock held by Venrock Associates VII, L.P., 428,744 shares of convertible preferred stock held by Venrock Healthcare Capital Partners II, L.P., 31,663 shares of convertible preferred stock held by Venrock Partners VII, L.P. and 173,847 shares of convertible preferred stock held by VHCP Co-Investment Holdings II, LLC.
  • [F4]Venrock Management VII, LLC ("VM7") is the sole general partner of Venrock Associates VII, L.P. ("VA7") and Venrock Partners VII, L.P. ("VP7") and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA7 and VP7 except to the extent of its indirect pecuniary interest therein. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP2") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest 2"), may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of its indirect pecuniary interest therein. Bong Koh and Nimish Shah are the managing members of VHCP Management II, LLC. Drs. Koh and Shah expressly disclaim beneficial ownership over all shares held by VHCP2 and VHCP Co-Invest 2 except to the extent of their indirect pecuniary interests therein.

Issuer

ShockWave Medical, Inc.

CIK 0001642545

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001614766

Filing Metadata

Form type
4
Filed
Mar 12, 8:00 PM ET
Accepted
Mar 13, 4:31 PM ET
Size
24.9 KB